17 results on '"Flaherty, John F."'
Search Results
2. Sa1640 LONG-TERM SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS; FINAL 8-YEAR RESULTS OF 2 PHASE 3 STUDIES
3. Sa1618 EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
4. Mo1537 EFFICACY AND SAFETY OF BULEVIRTIDE MONOTHERAPY GIVEN AT 2 MG OR 10 MG DOSE LEVEL ONCE DAILY FOR TREATMENT OF CHRONIC HEPATITIS DELTA: WEEK 48 PRIMARY ENDPOINT RESULTS FROM A PHASE 3 RANDOMIZED, MULTICENTER, PARALLEL-DESIGN STUDY
5. 193 SAFETY AND EFFICACY AT 1 YEAR IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B (CHB) RECEIVING TENOFOVIR ALAFENAMIDE (TAF)
6. Sa1525 SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
7. Sa1522 EFFICACY AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS WITH RENAL IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
8. 405 – Efficacy and Safety Results 48 Weeks After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) Vs Continued Tdf Treatment in Virologically-Suppressed Patients with Chronic Hepatitis B (CHB)
9. 406 – Chronic Hbv Patients Who Switched to Tenofovir Alafenamide (TAF) After Either 2 Or 3 Years of Prior Tenofovir Disoproxil Fumarate (TDF) Treatment Demonstrated Improvement in Bone and Renal Safety
10. Sa1496 - 1 Year Safety and Efficacy Data in Chronic Hbv Patients with Risk Factors for Tenofovir Disoproxil Fumarate (TDF) after Switching from TDF to Tenofovir Alafenamide (TAF)
11. Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study
12. Sa1495 - Hbeag Loss and Seroconversion Predictors by Baseline Clinical Features and Viral Deep Sequencing of Treatment with Tenofovir Alafenamide Fumarate (TAF) or Tenofovir Disoproxil Fumarate (TDF) after 144 Weeks
13. Sa1489 - Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study
14. Sa1490 - Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study
15. Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA
16. Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B
17. Sa1046 Efficacy of 5 Years of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients With High Viral Load (HBV DNA =9 Log10 Copies/Ml)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.